Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM58JY)

Drug Name
Ziprasidone Drug Info
Synonyms
146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
Indication
Disease Entry ICD 11 Status REF
Bipolar disorder 6A60 Approved [1]
Schizoaffective disorder 6A21 Approved [1]
Schizophrenia 6A20 Approved [2]
Therapeutic Class
Antipsychotic Agents
Cross-matching ID
PubChem CID
60854
ChEBI ID
CHEBI:10119
CAS Number
CAS 146939-27-7
TTD Drug ID
DMM58JY
VARIDT Drug ID
DR00810
INTEDE Drug ID
DR1732
ACDINA Drug ID
D00742

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [10]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [11]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [12]
EVP-6124 DMLQO7F Alzheimer disease 8A20 Phase 3 [13]
GTS-21 DMEN5KA Parkinson disease 8A00.0 Phase 2 [14]
JNJ-39393406 DMUOEKM Depression 6A70-6A7Z Phase 2 [15]
ABT-126 DM2OS51 Alzheimer disease 8A20 Phase 2 [16]
TC-6987 DMNFP21 Asthma CA23 Phase 2 [17]
AQW-051 DMD2RFO Alzheimer disease 8A20 Phase 2 [18]
MEM-3454 DMPNDYU Schizophrenia 6A20 Phase 2 [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [19]
Haloperidol DM96SE0 Delirium Approved [20]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [21]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [22]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [23]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [24]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [25]
Pimozide DMW83TP Schizophrenia 6A20 Approved [26]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [27]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [29]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [30]
Methotrexate DM2TEOL Anterior urethra cancer Approved [31]
Folic Acid DMEMBJC Colorectal carcinoma Approved [32]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [31]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [31]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [33]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [31]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [34]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [36]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [37]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [38]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [41]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [42]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [43]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [37]
Verapamil DMA7PEW Angina pectoris BA40 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lathosterol oxidase (SC5D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
Fluoxetine DM3PD2C Bipolar depression Approved [46]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [48]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [49]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [6]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
Haloperidol DM96SE0 Delirium Approved [6]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [53]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [54]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [55]
Digoxin DMQCTIH Arrhythmia BC9Z Approved [56]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [57]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [58]
Quercetin DM3NC4M Obesity 5B81 Approved [59]
Fluoxetine DM3PD2C Bipolar depression Approved [46]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [47]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [62]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [63]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [63]
Quercetin DM3NC4M Obesity 5B81 Approved [64]
Fluoxetine DM3PD2C Bipolar depression Approved [63]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [47]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [65]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [67]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [56]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [68]
Diazepam DM08E9O Alcohol withdrawal Approved [69]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [70]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [58]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [71]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [72]
Methotrexate DM2TEOL Anterior urethra cancer Approved [73]
Quercetin DM3NC4M Obesity 5B81 Approved [74]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [75]
Quinidine DMLPICK N. A. N. A. Approved [76]
Verapamil DMA7PEW Angina pectoris BA40 Approved [77]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [78]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [78]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [79]
Propranolol DM79NTF Angina pectoris BA40 Approved [80]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [81]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [82]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [78]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transcription factor SOX-17 (SOX17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [9]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [9]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [9]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [9]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [9]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [9]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [83]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [84]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [9]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [85]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [3]
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Binder [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Aldehyde oxidase (AOX1) Main DME DEAWHS8 AOXA_HUMAN Substrate []

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Gene/Protein Processing [6]
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [7]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Gene/Protein Processing [6]
Lathosterol oxidase (SC5D) OT41KMW4 SC5D_HUMAN Gene/Protein Processing [6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [8]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Protein Interaction/Cellular Processes [9]

References

1 Ziprasidone FDA Label
2 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
3 Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17.
4 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
5 Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
6 Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
7 Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content. Chem Biol Interact. 2019 Sep 25;311:108787. doi: 10.1016/j.cbi.2019.108787. Epub 2019 Aug 7.
8 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
9 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
10 Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
11 Clinical pipeline report, company report or official report of Roche (2009).
12 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
13 Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
14 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
15 Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
16 A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
17 ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
18 AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
19 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
20 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
21 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
22 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
23 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
25 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
26 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
27 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
28 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
31 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
32 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
33 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
34 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
35 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
36 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
37 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
38 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
39 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
40 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
41 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
42 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
43 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
44 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
45 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
46 Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
47 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
48 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
49 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
50 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
51 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
52 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
53 Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
54 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
55 Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
56 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
57 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
58 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
59 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
60 PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002 Jun 5;520(1-3):177-81.
61 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
62 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
63 Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
64 Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
65 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
66 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
67 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
68 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
69 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
70 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
71 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
72 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
73 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
74 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
75 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
76 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
77 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
78 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
79 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
80 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
81 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
82 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
83 Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
84 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
85 Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.